English (UK)
中文版
Dr Lihua Zheng
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
AnHeart Therapeutics
CBO & co-Founder
Linda Zheng
A French PHARMA & cosmetics company
Pierre Fabre Medicament China
Senior Market Access & Health Economics Directoryanfei zhou
ZhongXi Capital focus on biomedical investment，fiancing，consulting and other capital market business.
ZhongXi Capital
高级投资经理Ivy Zhou
Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.
Responsive Web Design powered by 